Upadhyay Rohit Kumar, Kumar Kuldeep, Vishwakarma Vishal Kumar, Singh Nirmal, Narang Rajiv, Parakh Neeraj, Yadav Mayank, Yadav Sangeeta, Kumar Sachin, Goyal Ahsas, Yadav Harlokesh Narayan
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, (Punjab)-147002-India.
Curr Vasc Pharmacol. 2025;23(1):12-30. doi: 10.2174/0115701611308870240910115023.
Cardiovascular disorders (CVDs) are reported to occur with very high rates of incidence and exhibit high morbidity and mortality rates across the globe. Therefore, research is focused on searching for novel therapeutic targets involving multiple pathophysiological mechanisms. Oxidative stress plays a critical role in the development and progression of various CVDs, such as hypertension, pulmonary hypertension, heart failure, arrhythmia, atherosclerosis, ischemia- reperfusion injury, and myocardial infarction. Among multiple pathways generating reactive oxygen species (ROS), Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases of the NOX family as the major source of ROS generation and plays an intricate role in the development and progression of CVDs. Therefore, exploring the role of different NADPH oxidase isoforms in various cardiovascular pathologies has attracted attention to current cardiovascular research. Focusing on NADPH oxidases to reduce oxidative stress in managing diverse CVDs may offer unique therapeutic approaches to prevent and treat various heart conditions. The current review article highlights the role of different NADPH oxidase isoforms in the pathophysiology of various CVDs. Moreover, the focus is also to emphasize different experimental studies that utilized various NADPH oxidase isoform modulators to manage other disorders. The present review article considers new avenues for researchers/scientists working in the field of cardiovascular pharmacology utilizing NADPH oxidase isoform modulators.
据报道，心血管疾病（CVDs）在全球范围内的发病率极高，且具有高发病率和高死亡率。因此，研究重点在于寻找涉及多种病理生理机制的新型治疗靶点。氧化应激在各种心血管疾病的发生和发展中起着关键作用，如高血压、肺动脉高压、心力衰竭、心律失常、动脉粥样硬化、缺血再灌注损伤和心肌梗死。在产生活性氧（ROS）的多种途径中，NOX家族的烟酰胺腺嘌呤二核苷酸磷酸（NADPH）氧化酶作为ROS产生的主要来源，在心血管疾病的发生和发展中发挥着复杂的作用。因此，探索不同NADPH氧化酶亚型在各种心血管病理中的作用已引起当前心血管研究的关注。专注于NADPH氧化酶以减轻氧化应激来管理各种心血管疾病，可能会提供独特的治疗方法来预防和治疗各种心脏疾病。当前的综述文章强调了不同NADPH氧化酶亚型在各种心血管疾病病理生理学中的作用。此外，重点还在于强调利用各种NADPH氧化酶亚型调节剂来管理其他疾病的不同实验研究。本综述文章为心血管药理学领域的研究人员/科学家利用NADPH氧化酶亚型调节剂考虑了新的途径。
